dm+d
422267005
Articles
Colistimethate Sodium products: information for supporting intrathecal risk assessment
11 August 2022Colistimethate products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Compatibility of nebuliser solution combinations
22 June 2022Guidance on what to consider when mixing nebuliser solutions and advice on which combinations are compatible.
Safety in Lactation: Some other antibacterials
4 November 2020Monitor infant for gastro-intestinal disturbances and oral candida infection, especially if used for prolonged periods or in high doses, although these effects are unlikely to…
Lactation Safety Information
Minimal absorption from the infant's GI tract
No published evidence of safety
Small amounts in breast milk
24 September 2020
New Medicines
Promixin Non-cystic fibrosis (CF)-related bronchiectasis - first-line in patients colonised with Pseudomonas aeruginosa
Information
Promixin
Licence extension / variation
Zambon
Zambon
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Category
The pentasodium salt derivative of colistin, a polypeptide antibiotic produced by Bacillus polymyxa var. colistinus
A large study across 640 general practices in the UK found that prevalence in 2011 in men was 227 per 100,000, and 309 per 100,000 in women. It is estimated that around 1,000 people die each year from bronchiectasis in England and Wales. Chronic colonisation by P. aeruginosa, severe exacerbations, and systemic inflammation (raised C-reactive protein) are associated with disease progression in non-cystic fibrosis bronchiectasis. 10% of adults die within 5-8 years of diagnosis [1].
Non-cystic fibrosis (CF)-related bronchiectasis - first-line in patients colonised with Pseudomonas aeruginosa
Inhalation